Vertex Pharma Stock Surges After FDA Approves Non-Opioid Pain Drug
Analyst is bullish on Vertex Pharmaceuticals, citing FDA approval for JOURNAVX and strong earnings growth potential in 2025.
Scientific American1d
What Is Journavx, the New Opioid-Free Painkiller from Vertex?
The nonaddictive painkiller suzetrigine (Journavx) is as effective for acute pain as a common opioid treatment ...
STAT2d
Cargo to lay off staff after CAR-T data show safety concerns
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
F.D.A. Approves Drug to Treat Pain Without Opioid Effects
The drug, Journavx by Vertex Pharmaceuticals, blocks pain signals to the brain, making it nonaddictive. The Food and Drug ...
Pharmabiz23h
Vertex Pharmaceuticals’ suzetrigine gets US FDA approval for treatment of adults with moderate-to-severe acute pain
Vertex Pharmaceuticals’ suzetrigine gets US FDA approval for treatment of adults with moderate-to-severe acute pain: Boston Saturday, February 1, 2025, 14:00 Hrs [IST] Vertex Ph ...
FDA approves new, non-opioid painkiller Journavx
The drug, shown to be almost as effective as opioids for short-term pain, is the first fundamentally new kind of painkiller ...
FiercePharma2d
Vertex scores FDA nod for long-awaited non-opioid pain reliever Journavx
Vertex has gained the FDA's approval for its nonaddictive pain med Journavx, which becomes the first significant innovation ...
What Is Journavx? First Pain Medication Approved by FDA in Over Two Decades
This milestone marks a breakthrough after unsuccessful attempts to develop painkillers without the addictive potential of ...
Vertex Pharmaceuticals Stock Jumps as Non-Opioid Painkiller Gets FDA Approval
Key Takeaways Vertex Pharmaceuticals' non-opioid painkiller received approval from the Food and Drug Administration.The drugmaker said the twice-daily pill, Journavx, is the first such treatment to ...
Vertex Pharmaceuticals Shares Are Up Today: What's Going On?
Vertex Pharmaceuticals Inc. (NASDAQ: VRTX) shares are trading higher Friday following two major developments that strengthen ...
AFP2d
Vertex Announces FDA Approval of JOURNAVX™ (suzetrigine), a First-in-Class Treatment for Adults With Moderate-to-Severe Acute Pain
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the U.S. Food and Drug Administration (FDA) has ...
FDA Approves Vertex Pharma's JOURNAVX As The First Drug In A New Class Of Non-Opioid Pain Medicines
Vertex Pharmaceuticals Inc. (VRTX) has secured FDA approval for Suzetrigine, an oral, non-opioid, highly selective NaV1.8 pain signal ...